Although our sample size is limited, this effect seemed to be driven by the survival of patients with ERBB2-amplified tumours who all received trastuzumab-based therapy (as expected), but also by the overall survival of patients with other alterations who received matched therapy. Here, ERBB2 is linked to neoplasm.